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http://www.dmsjournal.com/content/6/1/24RESEARCH Open AccessEffect of moderate alcohol consumption on
fetuin-A levels in men and women: post-hoc
analyses of three open-label randomized
crossover trials
Michel M Joosten1,2,3*, Ilse C Schrieks1,2 and Henk FJ Hendriks1Abstract
Background: Fetuin-A, a liver-derived glycoprotein that impairs insulin-signalling, has emerged as a biomarker for
diabetes risk. Although moderate alcohol consumption has been inversely associated with fetuin-A, data from
clinical trials are lacking. Thus, we evaluated whether moderate alcohol consumption decreases circulating levels of
fetuin-A.
Methods: We analyzed data of three separate open-label, randomized, crossover trials: 1) 36 postmenopausal
women consuming 250 ml white wine (25 g alcohol) or white grape juice daily for 6 weeks, 2) 24 premenopausal
women consuming 660 ml beer (26 g alcohol) or alcohol-free beer daily for 3 weeks, and 3) 24 young men
consuming 100 ml vodka (30 g alcohol) orange juice or only orange juice daily for 4 weeks. After each treatment
period fasting blood samples were collected.
Results: Circulating fetuin-A concentrations decreased in men after vodka consumption (Mean ± SEM: 441 ± 11 to
426 ± 11 μg/ml, p = 0.02), but not in women after wine (448 ± 17 to 437 ± 17 μg/ml, p = 0.16) or beer consumption
(498 ± 15 to 492 ± 15 μg/ml, p = 0.48) compared to levels after each corresponding alcohol-free treatment. Post-hoc
power analyses indicated that the statistical power to detect a similar effect as observed in men was 30% among
the postmenopausal women and 31% among the premenopausal women.
Conclusions: In these randomized crossover trials, moderate alcohol consumption decreased fetuin-A in men but
not in women. This sex-specific effect may be explained by the relatively short intervention periods or the low
statistical power in the trials among women.
Trials registration: ClinicalTrials.gov ID no’s: NCT00285909, NCT00524550, NCT00918918.
Keywords: Alcohol consumption, Fetuin-A, Insulin sensitivity, Liver enzymes, Type 2 diabetes mellitusIntroduction
Fetuin-A (α-Heremans-Schmid glycoprotein) is an abun-
dant hepatokine that impairs insulin signalling by inhibiting
tyrosine kinase activity [1,2]. Several prospective studies
have reported positive associations between circulating
fetuin-A and type 2 diabetes risk and, concomitantly,* Correspondence: mmjoosten@gmail.com
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unless otherwise stated.observed inverse relations between alcohol consumption
and fetuin-A [3-5]. More importantly, a recent case-control
study suggested that fetuin-A may partially explain the re-
duced risk of type 2 diabetes [6] that has consistently been
observed with moderate alcohol consumption [7-9]. How-
ever, the cross-sectional and observational nature of these
alcohol-fetuin-A associations may raise concern about po-
tential confounding. Thus, to comprehensively investigate
the effect of moderate alcohol consumption on fetuin-A
levels, we performed post-hoc analyses of three randomizedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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beverages in men and women.
Materials and methods
The rationale of the three trials was to study the effect
of moderate alcohol consumption on markers of insulin
sensitivity and/or inflammation. Each trial is registered
at ClinicalTrials.gov: NCT00285909, NCT00524550, and
NCT00918918. Independent medical ethics committees
approved the research protocols (The Medical Ethics
Committee of the University Medical Centre Utrecht;
Utrecht, the Netherlands [NCT00285909] and METOPP;
Tilburg, the Netherlands [NCT00524550, and NCT00918918])
and all participants gave written informed consent.
Eligible subjects were apparently healthy, were habitual
alcohol consumers, refrained from smoking, and had
no family history of alcoholism. The design of each
individual intervention has been described in more de-
tail elsewhere [10-12]. In short, the three studies were
open-label, randomized, crossover intervention trials
and were all conducted at TNO (a Dutch acronym for
Netherlands Organisation of Applied Scientific Research)
in Zeist, the Netherlands. The trials consisted of 1) 36
postmenopausal women consuming 250 ml white wine
(25 g alcohol; Chardonnay; Jean d’Alibert, Rieux, France)
or white grape juice (Albert Heijn, Zaandam, the
Netherlands) daily for 6 weeks between March and
June 2006, 2) 24 premenopausal women consuming
660 ml beer (26 g alcohol) or alcohol-free beer
daily (both Amstel, Amsterdam, the Netherlands) for 3
weeks between August and November 2007, and 3) 24
young men consuming 100 ml vodka (30 g alcohol;
Smirnoff, Diageo, London, UK) and 200 ml orange juice
(Appelsientje, Riedel, Ede, The Netherlands) or only
orange juice daily for 4 weeks between August and
November 2009. Postmenopausal women had an absence
of menses for at least two years. Premenopausal women
used phase I or II oral contraceptives. Allocation to treat-
ment order (alcohol-containing vs. alcohol-free period)
was randomized according to age and body mass index
(BMI). After each treatment period, fasting blood samples
were obtained. Plasma samples were stored at −80°C (beer
and vodka trials) and serum samples at −20°C (wine trial)
until analysis. Fetuin-A concentrations were determined
by a sandwich enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Minneapolis, MN) with a mean
intra-assay coefficient of variation of 6.8%.
Data were analyzed using SAS statistical software (ver-
sion 8.2; SAS Institute, Cary, NC, USA). Variables were
compared between treatments with a mixed analysis of
variation (ANOVA) model that included terms for treat-
ment, period and the interaction between period and
treatment (indicating possible carryover effects). Correl-
ation coefficients were computed according to Spearmanrank order to assess associations between intervention-
induced changes in fetuin-A and other biochemical vari-
ables. Data are presented as mean ± standard error of
the mean (SEM). All tests were two-sided. Statistical sig-
nificance was defined as p < 0.05.
Results
All subjects completed both arms of their intervention.
No notable adverse effects were reported. Age and BMI
were 56.5 ± 4.2 y and 25.4 ± 3.3 kg/m2 in postmenopausal
women, 23.9 ± 4.3 y and 22.2 ± 1.6 kg/m2 in the premeno-
pausal women, and 25.5 ± 4.3 y and 22.2 ± 1.6 kg/m2 in
the men, respectively. Indicators of compliance were the
increased high-density lipoprotein (HDL)-cholesterol and
adiponectin levels after each of the three alcohol con-
sumption periods compared with after the alcohol-free
consumption periods (Table 1).
No carry-over effects were found in fetuin-A, indicat-
ing that a possible effect on fetuin-A levels due to a
treatment given in the first time period of the crossover
trial did not persist into the second period and influence
the effect of the second treatment. Fetuin-A levels de-
creased in men after vodka juice consumption (441 ± 11
to 426 ± 11 μg/ml, p = 0.02) but not significantly in post-
menopausal women after wine (448 ± 17 to 437 ± 17 μg/
ml, p = 0.16) or in premenopausal women after beer con-
sumption (498 ± 15 to 492 ± 15 μg/ml, p = 0.48) (Figure 1)
as compared to levels after each corresponding alcohol-
free beverage consumption.
No correlations were observed between alcohol-induced
changes in fetuin-A and corresponding changes in the
homeostasis model assessment of insulin resistance
(HOMA-IR) (ρ = 0.01, p = 0.95; ρ = 0.25, p = 0.26; ρ = 0.20,
p = 0.24) or changes in adiponectin (ρ = 0.22, p = 0.31;
ρ = 0.17, p = 0.44; ρ = 0.25, p = 0.15) among young men,
pre- or postmenopausal women, respectively. Changes in
HOMA-IR and adiponectin were also not correlated
among men (ρ = 0.14, p = 0.51), premenopausal women
(ρ = 0.01, p = 0.96), or postmenopausal women (ρ = 0.27,
p = 0.11). Also, no consistent correlations were observed
between alcohol-induced changes in fetuin-A and
analogous changes in fasting blood lipids including
HDL-cholesterol and free fatty acids (FFA), or liver
function parameters across the three trials.
Conclusions
In post-hoc analyses of three separate open-label ran-
domized crossover intervention studies, we found that
moderate alcohol consumption reduced fetuin-A levels
in men but not in women. This decrease was apparent
after four weeks of moderate vodka consumption. No
consistent correlations between intervention-induced
changes in fetuin-A and other biochemical markers were
observed across the three studies.
Table 1 Biochemical markers of 24 young men, 24 premenopausal women, and 36 postmenopausal women sampled
after an overnight fast after 4, 3 and 6-week treatment periods, respectively, of consuming alcohol-free or
alcohol-containing beverages

















Fetuin-A (μg/ml) 441 ± 11 426 ± 11 0.02 498 ± 15 492 ± 15 0.48 448 ± 17 437 ± 17 0.16
Adiponectin (μg/ml) 10.5 ± 1.0 11.8 ± 1.0 0.005 6.8 ± 0.4 7.2 ± 0.4 0.01 12.0 ± 0.7 13.1 ± 0.7 <0.001
Insulin (pmol/l) 59.8 ± 8.5 55.7 ± 8.6 0.53 45.7 ± 4.0 46.1 ± 4.0 0.90 46.5 ± 3.4 40.0 ± 3.4 0.90
Glucose (mmol/l) 5.3 ± 0.10 5.3 ± 0.10 0.76 4.8 ± 0.11 4.8 ± 0.11 0.36 5.4 ± 0.11 5.4 ± 0.11 0.36
HOMA-IR 1.98 ± 0.30 1.87 ± 0.30 0.61 1.41 ± 0.11 1.43 ± 0.11 0.81 1.64 ± 0.13 1.42 ± 0.13 0.02
HDL cholesterol (mmol/l) 1.12 ± 0.05 1.22 ± 0.05 0.009 1.52 ± 0.07 1.62 ± 0.07 0.008 1.57 ± 0.07 1.68 ± 0.07 <0.001
LDL cholesterol (mmol/l) 2.63 ± 0.17 2.70 ± 0.17 0.55 2.40 ± 0.07 2.37 ± 0.07 0.77 3.84 ± 0.12 3.51 ± 0.12 <0.001
Triglycerides (mmol/l) 1.23 ± 0.14 1.33 ± 0.14 0.30 1.27 ± 0.08 1.25 ± 0.08 0.61 1.18 ± 0.08 1.04 ± 0.08 <0.001
Free fatty acids (mmol/l) 0.42 ± 0.03 0.35 ± 0.03 0.07 0.34 ± 0.03 0.29 ± 0.03 0.26 0.43 ± 0.04 0.44 ± 0.04 0.67
Alanine aminotransferase (U/l) 15.2 ± 1.1 15.9 ± 1.1 0.49 10.8 ± 1.8 10.0 ± 1.8 0.21 13.8 ± 2.5 17.4 ± 2.5 0.29
Alkaline phosphates (U/l) 65.1 ± 4.3 65.8 ± 4.3 0.70 56.9 ± 6.5 57.8 ± 6.5 0.68 72.7 ± 2.9 73.6 ± 2.9 0.73
Aspartate aminotransferase (U/l) 21.0 ± 1.0 20.6 ± 1.0 0.62 17.8 ± 2.0 17.8 ± 2.0 0.95 20.9 ± 2.0 24.8 ± 2.0 0.13
γ-Glutamyltransferase (U/l) 19.8 ± 2.4 24.3 ± 2.4 0.003 16.5 ± 2.2 18.5 ± 2.2 0.01 18.4 ± 5.2 27.5 ± 5.2 0.21
Data are presented as means ± SEM. P values are obtained from a mixed-model ANOVA. Abbreviations: HOMA-IR homeostasis model assessment of insulin
resistance; HDL high-density lipoprotein; LDL low-density lipoprotein.
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studies investigating the effect of different alcohol-
containing beverages on circulating fetuin-A. The low-
ered fetuin-A levels in men after moderate alcohol
consumption partially confirm cross-sectional observa-
tions in several epidemiological studies [3-6,13,14] and
may provide some physiological support for the protect-
ive effect of moderate alcohol consumption on the risk
of developing type 2 diabetes [6,8] besides adiponectin
[15]. Furthermore, these findings extend prior evidence
of short-term clinical trials that noted favourable
changes in selected biological markers associated with
diabetes and cardiovascular risk after moderate alcohol
consumption [16].
The underlying physiological explanation how alcohol
consumption may lower fetuin-A is not clear. Also, the
sex-specific alcohol-fetuin-A effect was unexpected, par-
ticularly since all women were either on oral contraceptives
or postmenopausal, which limits potential influences of
hormonal fluctuations or menstrual cycles. The null finding
in our trials among pre- and postmenopausal women do
not seem to correspond with a previous observational study
among 1331 middle-aged and older US female nurses,
where moderate alcohol consumption was inversely associ-
ated with plasma fetuin-A even after adjustment for several
lifestyle variables, demographic information, and medical
history [6]. Perhaps this discrepancy can be explained by
the low statistical power in the two trials among women.
Post-hoc power analyses indicated that the power to detect
a similar effect as observed in men was only 30% amongthe postmenopausal women and 31% among the premeno-
pausal women.
Circulating fetuin-A was strongly and negatively asso-
ciated with the insulin-sensitizing adipokine adiponectin
in humans [17] and treatment of human adipocytes with
fetuin-A repressed ADIPOQ mRNA levels [17]. Further-
more, given the prior associations between fetuin-A and
insulin resistance [18] and insulin sensitivity [19], we hy-
pothesized that reductions in fetuin-A may play a role in
the increased adiponectin levels or improved insulin sen-
sitivity after alcohol consumption [10]. Therefore, we ana-
lyzed correlations between intervention-induced changes
in fetuin-A and adiponectin levels and other markers of
insulin sensitivity, such as HOMA-IR. We, however, did
not find such inverse correlations despite the fact that
moderate alcohol consumption increased both ADIPOQ
expression [10] and corresponding circulating adiponectin
levels [10-12], suggesting that fetuin-A and adiponectin
levels may be independently affected by alcohol. Also, it is
important to note that the HOMA-IR index is a weak esti-
mate of insulin resistance, particularly in a small study.
The absence of a correlation between alcohol-induced
changes in fetuin-A and HOMA-IR may partially be ex-
plained by the relatively low FFA levels of the studied par-
ticipants. In a study among 347 healthy subjects at
increased risk of type 2 diabetes, fetuin-A was only in-
versely associated with insulin sensitivity among individ-
uals with high FFA levels (~ > 0.65 mmol/l) [20].
Strengths of the study are the randomized crossover
design (considered the ‘gold standard’ for evidence-based
Figure 1 Individual changes of circulating fetuin-A levels at the end of the alcohol or alcohol-free treatment periods after an overnight
fast for three open-label randomized crossover trials.
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HDL-cholesterol and adiponectin) to the study treat-
ments, the inclusion of both sexes, and the broad range
of biochemical variables. Some limitations warrant con-
sideration. The trials consisted of alcohol-administration
periods of 3 to 6 weeks and were performed among
fairly insulin-sensitive subjects. Maybe more profound
effects on fetuin-A levels would have been observed if
the interventions lasted longer and/or were executed in
subjects with glucose levels in the (pre)diabetic range.
For example, three months of moderate alcohol con-
sumption decreased fasting glucose levels among sub-
jects with impaired glucose metabolism [21] and fetuin-A
levels were particularly associated with an increased
diabetes risk among subjects with higher fasting glucose
[3,5]. Regardless, the duration of the present interven-
tions were long enough to detect alcohol-induced
changes in other biochemical markers such as adiponec-
tin and HDL-cholesterol. Also, the association between
moderate alcohol consumption and lower risk of type 2
diabetes mellitus is not limited to subjects with impaired
glucose metabolism but also exists for subjects already
at low risk for diabetes on the basis of multiple com-
bined low-risk lifestyle behaviours [22]. Nevertheless, the
subjects studied were rather lean (mean BMI values 22-
26), had no fatty liver (low liver enzyme levels) and were
rather insulin sensitive (low HOMA-IR). Also, all pre-
menopausal women used oestrogen-containing oral con-
traceptives, which may explain their somewhat higher
fetuin-A levels given the positive associations between
oestrogen and fetuin-A [23,24]. Thus, the data are not
representative for a typical at-risk population for meta-
bolic diseases. Second, the daily amounts of alcohol con-
sumed by women (~25 g alcohol) were higher than what
is considered ‘moderate’ according to most guidelines (i.e.
max. ~15 g alcohol). However, the nadir of the alcohol-diabetes association for women appeared to be at 24 g of
alcohol/day in a meta-analysis of 20 prospective studies
[8] while alcohol consumption became harmful above
50 g/day (and above 60 g/day for men). Third, post-hoc
power analyses showed that there was low statistical
power in the two trials among women to detect a similar
effect as observed in the trial among men. Fourth, al-
though unlikely since vodka is basically an ethanol-
water mixture, we cannot fully exclude a potential
beverage-specific effect. Finally, the alcohol-induced re-
ductions in fetuin-A were comparable to associations
reported in epidemiological studies [3,5,6], but were
relatively small as compared to alcohol’s effect on
HDL-cholesterol and adiponectin. It is possible that the
findings, including the sex differences, were due to
chance.
In conclusion, the results of these three randomized
clinical trials with different alcohol-containing beverages
demonstrated that short-term moderate alcohol con-
sumption decreases fetuin-A levels in men but not in
women. Further research is needed to determine
whether long-term moderate alcohol consumption de-
creases fetuin-A levels. If so, these findings may add to
the current knowledge of possible metabolic benefits of
moderate alcohol consumption.
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